Park, J.R., Digiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechovet, H.B., Bautista, C., Chang, W.C., Ostberg, J.R., Jensen, M.C. Adoptive Transfer of Chimeric Antigent Receptor RE-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. Molecular Therapy 2007 [Epub ahead of print].
Parsa, A.T., Waldron, J.S., Panner, A., Crane, C.A., Parney, I.F., Barry, J.J., Cachola, K.E., Murray, J.C., Tihan, T., Jensen, M.C., Mischel, P.S., Stokoe, D., Pieper, R.O. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Med., 13(1):84-8, 2007.
Pameijer, C., Navanjo, A., Meechoovet, B., Wagner, J., Aguilar, B., Wright, C., Chang, W., Brown, C., and Jensen, M. Conversion of a Tumor-Binding Peptide Identified by Phage Display to a Functional Chimeric T-cell Antigen Receptor. Cancer Gene Therapy, 14:91-97, 2007.
Nubenjapon, T., Serrano, L.M., Singh, H., Kowolik, C.M., Olivares, S., Gonzalez, N., Chang, W.C., Forman, S.J., Jensen, M.C., Cooper, L.J., Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells, Leukemia, 20(10):1889-92, 2006.
Kowolik, C.M., Topp, M.S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D.D., Forman, S., Jensen, M.C., Cooper, L.J. CD28 constimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research, 66(22):10995-1004, 2006.
Cooper, L.J.N., Ausubel, L., Gutierrez, M., Stephan, S., Shakeley, R., Olivares, S., Serrano, L.M., Burton, L., Jensen, M.C.V., Forman, S.J. and DiGiusto, D.L. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma Cytotherapy, 8(2):105-117, 2006.
Yam, P., Jensen, M., Akkina, R., Anderson, J., Villacres, M.C., Wu, J., Zaia, J.A. and Yee, J.K.
Ex Vivo Selection and Expansion of Cells Based on Expression of a Mutated Inosine Monophosphate Dehydrogenase 2 after HIV Vector Transduction: Effects on Lymphocytes, Monocytes, and CD34(+) Stem Cells. Mol Therapy; 14(2):236-44, 2006.
Otto-Duessel M., Khankaldyyan V., Gonzalez-Gomez I., Jensen M.C., Laug W.E., Rosol M. In Vivo Testing of Renilla Luciferase Substrate Analogs in an Orthotopic Murine Model of Human Glioblastoma. Mol Imaging, 5(2): 57-64, 2006.
Serrano, L.M., Pfeiffer, T., Olivares, S. Numbenjapon, T., Bennitt, J., Kim, D., Smith, D., McNamara, G., Al-Kadhimi, Z., Rosenthal, J., Forman, S.J. Jensen, M.C. and Cooper, L.J. Differentiation of naïve cord blood T cells into CD19-specific cytolytic effectors for post-transplant adoptive immunotherapy. Blood; 107(7):2643-52, 2006.
Morris, K., Castanotto, D., Al-Kadhimi, Z., Jensen, M., Rossi, J. Cooper ,L.J. Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology, 10(6):461-7, 2005.
Gonzalez, S., Castanotto, D., Li, H., Olivares, S., Jensen, M.C., Forman, S.J., Rossi, J.J., Cooper, L.J. Amplification of RNAi-targeting HLA mRNAs. Mol Therapy, 11(5):811-8, 2005.
Vishwanath, R.P., Brown, C.E., Wagner, J.R., Meechoovet, H.B., Naranjo, A., Wright, C.L., Olivares, S., Qian, D., Cooper, L.J., and Jensen, M.C. A Quantitative High-throughput Chemotaxis Assay Using Bioluminescent Reporter Cells. J Immunol Methods, 302(1-2):78-89, 2005.
Cooper, L.J.N., Castanotto D, Gonzalez, S., Li H., Olivares, S., Serrano, L.M., Jensen, M.C., Forman, S.J., and Rossi J. Amplification of RNAi-effect. Mol Therapy, 11(5):811-818, 2005.
Jensen, M., Strategies to Enhance the Therapeutic Efficacy of Autologous Hematopoietic Stem Cell Transplantation by Posttransplantation Adoptive Transfer of T Cells with Engineered Graft-versus-Tumor Activity. Biology of Blood and Marrow Transplantation, (11):34-39, 2005.
Brown, C.E., Wright, C.L., Naranjo, A., Vishwanath, R.P., Chang, W.-C., Olivares, S., Wagner, J.R., Bruins, L., Raubitschek, A., Cooper, L.J.N., and Jensen, M.C.: Biophotonic Cytotoxicity Assay for High-Throughput Screening of Cytolytic Killing. J Immunol Methods, 297:39-52, 2005.
Cooper, L.J.N., Al-Kadhimi, Z., Serrano, L.M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.-C., Gonzalez, S., Smith, D., Forman, S.J., and Jensen, M.C.: Enhanced Antilymphoma Efficacy of CD19-Redirected Influenza MP1-Specific CTL's by Co-Transfer of T Cells Modified to Present Influenza MP1. Blood, 105(4):1622-31, 2005.
Kahlon, K.S., Brown, C., Cooper, L.J.N., Raubitschek, A., Forman, S.J., and Jensen, M.C.: Specific Recognition and Killing of Glioblastoma Multiforme by IL13-Zetakine Re-Directed Cytolytic T-Cells. Cancer Research, 64(24):9160-66, 2004.
Cooper, L.J.N., Topp, M.S., Pinzon, C, Jensen, M.C., Riddell, S.R., and Greenberg P.D. Enhanced transgene expression in quiescent and activated human CD8+ T cells. Human Gene Therapy. 15(7):648-58, 2004.
Cooper, L.J., Al-Kadhimi, Z., DiGiusto, D., Kalos, M., Colcher, D., Raubitschek, A., Forman, S.J., and Jensen, M.C. Development and Application of CD19-Specific T Cells for Adoptive Immunotherapy of B cell Malignancies. Blood Cells, Molecules, & Diseases. 33(1):83-89, 2004.
Gonzalez, S., Naranjo, A., Serrano, L.M., Chang, W.-C., Wright, C.L., and Jensen, M.C. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. The Journal of Gene Medicine, 6(6):704-11, 2004.
Wang, J., Press, O.W., Lindgren, C.G., Greenberg, P., Riddell, S., Qian, X., Laugen, C., Raubitschek, A., Forman, S.J., and Jensen, M.C. Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes. Molecular Therapy, 9(4) 577-86, 2004.
Topp, M.S., Riddell, S.R., Akatsuka, Y., Jensen M.C., Blattman J.N. and Greenberg, P.D.: Restoration of CD28 Expression in CD28-CD8+ Memory Effector T-Cells Reconstitutes Antigen-Induced IL-2 Production. J Exp Med, 198(6):947-55, 2003.
Jensen, M.C., Cooper, L.J.N., Wu, A.M., Forman, S.J., Raubitschek, A.: Engineered CD20-Specific Primary Human Cytotoxic T Lymphocytes For Targeting B-Cell Malignancy. Cytotherapy, 5(2):131-138, 2003.
Cooper, L.N., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S.J., and Jensen, M.C.: T-Cell Clones Can Be Rendered Specific For CD19: Toward the Selective Augmentation of the Graft Versus B-Lineage Leukemia Effect. Blood, 101(4):1637-44, 2003.
Jensen, M.C. Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones. Cytotherapy, 4(5):443-4, 2002.
Jensen, M.C., Clarke, P., Tan, G., Wright, C., Chung-Chang, W., Clark, T.N. , Zhang, F., Slovak, M.L., Wu, A.M., Forman, S.J., Raubitschek, A.: Human T Lymphocyte Genetic Modification with Naked DNA. Mol Therapy, 1(1):49-55, 2000.
Jensen, M., Tan, G., Forman, S., Wu, A.M., Raubitschek, A.: CD20 is a molecular target for scFvFc: z receptor re-directed T cells: implications for cellular immunotherapy of CD20+ malignancy. Biology of Blood and Marrow Transplantation, 4:75-83, 1998.
Sing, A.P., Ambinder, R.F., Hong, D.J., Jensen, M., Batten, W., Petersdorf, E., and Greenberg, P.D.: Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood, 89(6):1978-86, 1997.
Greenberg, P.D., Nelson, B., Gilbert, M., Sing, A., Yee, C., Jensen, M.C., and Riddell, S.R.: Genetic modification of T cell clones to improve safety and efficacy of adoptive T cell therapy. In: Vaccines Against Virally Induced Cancers, Ciba Foundation Symposium, Chichester, 1994.
Greenberg, P.D., Kern, D.E., Klarnet, J.P., Jensen, M.C., Grabstein, K.H., and Cheever, M.A.: Specific adoptive therapy of disseminated tumors: Requirements for therapeutic efficacy and mechanisms by which T cells mediate tumor eradication. In: Induction and Recognition of the Transformed Cell, T. Hamaoka and M.I. Greene (eds.), Philadelphia, PA, 1987.
Greenberg, P.D., Kern, D.E., Jensen, M.C., Klarnet, J.P., and Cheever, M.A.: Effector mechanisms by which adoptively transferred T cells promote tumor eradication. In: Cellular Immunotherapy of Cancer, Progress in Clinical and Biological Research, Vol. 244, R.L. Truitt, R.P. Gale, and M.M. Bortin (eds.)., Philadelphia, PA, 1987.
Kern, D.E., Klarnet, J.P., Jensen, M.C.V., and Greenberg, P.D.: Requirement for recognition of Class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific Class I-restricted CTL. J of Immunol, 136(11):4303, 1986.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.
